Skip to main content

Table 3 PARP inhibitors in ovarian cancer—phase II–III ongoing studies

From: Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment

ClinicalTrials.gov Identifier

Responsible party

Ph

Drugs

NCT01033292

Sanofi

II

CBDC/GEM with INI in Pts with platinum-resistant recurrent EOC

NCT01033123

Sanofi

II

CBDC/GEM with INI in Pts with platinum-sensitive recurrent EOC

NCT00677079

Sanofi

II

INI in Pts with BRCA-1 or BRCA-2 associated advanced EOC

NCT01482715

Clovis Oncology, Inc.

II

RUC in Pts with gBRCA Mutation EOC

NCT01891344

Clovis Oncology, Inc.

II

RUC in Pts with platinum-sensitive, relapsed, HGSOC (ARIEL2)

NCT01968213

Clovis Oncology, Inc.

III

RUC as switch maintenance after platinum in relapsed HGSOC (ARIEL3)

NCT00664781

Cancer Research UK

II

RUC in known carriers of a BRCA 1 or BRCA 2 mutation with advanced EOC

NCT01690598

Vejle Hospital

II

VEL and TOP for Pts with platinum-resistant or partially platinum-sensitive relapse of EOC with negative or unknown BRCA status

NCT01472783

Vejle Hospital

II

VEL for Pts with BRCA germline mutation and platinum-resistant or partially platinum-sensitive relapse of EOC

NCT01113957

AbbVie (Abbott)

II

VEL with TEM vs PLD alone in subjects with recurrent HGSOC

NCT01306032

National Cancer Institute

II

VEL in combination with metronomic oral CYC in refractory BRCA-positive EOC

NCT02470585

AbbVie

III

CBDC/P with or without concurrent and continuation maintenance VEL in subjects with previously untreated stages III or IV HGSOC

NCT01540565

National Cancer Institute

II

VEL in persistent or recurrent EOC with germline BRCA1/BRCA2 mutation

NCT02392676

AstraZeneca

III

PLA controlled study of OLA maintenance in Pts With platinum sensitive relapsed EOC and loss of function somatic BRCA mutation(s) or loss of function mutation(s) in tumour homologous recombination repair-associated genes

NCT01874353

AstraZeneca

III

PLA controlled study of OLA maintenance in platinum sensitive relapsed BRCA mutated EOC Pts with a complete or partial response following platinum based CT

NCT02571725

New Mexico Cancer Care Alliance

II

Combination of OLA and TREM, in BRCA1 and BRCA2 mutation carriers with recurrent EOC

NCT01844986

AstraZeneca

III

OLA maintenance in Pts With BRCA mutated advanced EOC following first line platinum based CT

NCT01081951

AstraZeneca

III

OLA With P and CBDC vs P and CBDC alone in Pts with platinum sensitive advanced EOC

NCT02503436

AstraZeneca

II

OLA treated BRCAm EOC POPULATION

NCT02282020

AstraZeneca

III

OLA vs Physician’s choice single agent CT for platinum sensitive relapsed EOC in Pts carrying germline BRCA1/2 mutations

NCT02484404

National Institutes of Health Clinical Center (National Cancer Institute)

II

Anti-programmed death ligand-1 antibody MEDI4736 in combination With OLA or CED for advanced solid tumors and advanced or recurrent EOC

NCT02340611

University Health Network, Toronto

II

Combination CED-OLA at the time of disease progression on OLA in EOC

NCT01661868

Ursula A. Matulonis, MD, Dana-Farber Cancer Institute

II

OLA for Pts with recurrent BRCA deficient EOC with no prior PARP exposure or prior PARP inhibitor exposure

NCT02477644

ARCAGY/GINECO GROUP

III

OLA or PLA in with platinum-taxane and BV and as maintenance therapy

NCT02345265

National Cancer Institute

II

OLA and CED for the treatment of recurrent EOC

NCT02208375

M.D. Anderson Cancer Center

II

OLA With AZD2014 or AZD5363 for recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer

NCT02502266

National Cancer Institute

II/III

CED and OLA compared to CED or OLA alone, or standard of care CT in women with recurrent platinum-resistant or -refractory EOC

NCT02489006

University Health Network, Toronto

II

OLA in Pts with platinum sensitive recurrent HGSOC

NCT00628251

AstraZeneca

II

OLA vs intravenous liposomal doxorubicin given monthly in Pts with advanced BRCA1- or BRCA2-associated EOC who have failed previous platinum-based CT

NCT02485990

Sidney Kimmel Comprehensive Cancer Center

II

TREM alone or combined with OLA for recurrent or persistent EOC

NCT01116648

National Cancer Institute

II

CED and OLA for recurrent papillary-serous ovarian, fallopian tube, or peritoneal cancer or for treatment of recurrent TNBC

NCT01078662

AstraZeneca

II

OLA in Pts with advanced cancers BRCA 1 and/or BRCA2 mutation

NCT00494442

AstraZeneca

II

OLA twice daily in Pts with advanced BRCA1 or BRCA2 associated EOC

NCT00679783

AstraZeneca

II

OLA in Pts with known BRCA or recurrent HGSOC and in known BRCA or TNBC

NCT00753545

AstraZeneca

II

OLA Pts with platinum sensitive relapsed serous EOC following treatment with two or more platinum containing regimens

NCT02326844

National Institutes of Health Clinical Center (National Cancer Institute)

II

TAL in Pts with deleterious BRCA1/2 mutation-associated EOC who have had prior PARP inhibitor treatment

NCT01989546

National Cancer Institute

II

TAL in Pts with advanced solid tumors and deleterious BRCA mutations

NCT01847274

Tesaro, Inc.

III

Maintenance with NIR vs PLA in Pts with platinum sensitive EOC

NCT02354131

Nordic Society for Gynaecologic Oncology

II

NIR and/or NIR-BV combination against BV alone in HRD platinum-sensitive EOC

NCT02354586

Tesaro, Inc.

II

NIR in women with advanced, relapsed, HGSOC, fallopian tube, or primary peritoneal cancer who have received at least three previous CT regimens

NCT02657889

Tesaro, Inc.

II

NIR With PEM in Pts with advanced TNBC and in Pts with recurrent EOC

NCT02655016

Tesaro, Inc.

III

NIR maintenance in Pts With HRD-positive advanced EOC following response on front-line platinum-based CT

NCT02446600

National Cancer Institute

III

Comparing OLA or CED and OLA to standard platinum-based CT in women with recurrent platinum-sensitive EOC

NCT01434316

National Cancer Institute

I

VEL and DIN given together with or without CBDC

CRUK/13/023

Cancer Research UK

III

OLA with CED vs CED and PLA as maintenance therapy following platinum-based CT with CED

  1. Reference: https://www.clinicaltrials.gov; http://www.cancerresearchuk.org
  2. EOC epithelial ovarian cancer, OLA olaparib, VEL veliparib, CED cediranib, RUC rucaparib, DIN dinaciclib, NIR niraparib, TAL talazoparib, GEM gemcitabine, TOP topotecan, PEM pembrolizumab, TREM tremelimumab, CYC cyclophosphamide, TEM temozolomide, PLD pegylated liposomal doxorubicin, PLA placebo, mt mutated, wt wild type, Pts patients, P paclitaxel, CBDC carboplatin, TNBC triple-negative breast cancer, Ph phase